The goal of this clinical research study is to learn if Jakafi (ruxolitinib) can help to control fatigue and other symptoms in patients with CLL who do not need treatment for the cancer. Researchers also want to learn if ruxolitinib can decrease the size of enlarged lymph nodes and/or lower the number of CLL cells in the blood.